JNJ

162.06

0.41% 0.66

After Hours: 162.06

Johnson Johnson (JNJ)

Overview News Price History Option Chain Financials Why JNJ Down? Discussions Forecast Stock Split Dividend History

Johnson Johnson stock is traded at $162.06, with a volume of 5.34M. It is up +0.41% in the last 24 hours and down -2.29% over the past month.

Previous Close:

$161.40

Open:

$161.57

24h Volume:

5.34M

Relative Volume:

0.88

Market Cap:

$353.35B

Revenue:

$86.58B

Net Income/Loss:

$38.02B

P/E Ratio:

12.03

EPS:

13.47

Net Cash Flow:

$19.83B

1W Performance:

-0.71%

1M Performance:

-2.29%

6M Performance:

+2.45%

1Y Performance:

+4.05%

1-Day Range:

$160.68

$162.18

1-Week Range:

$160.02

$163.49

52-Week Range:

$143.13

$168.85

Johnson Johnson Stock (JNJ) Company Profile

Name

Johnson Johnson

Sector

Healthcare (1203)

Industry

Drug Manufacturers - General (17)

Phone

732-524-2455

Address

ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ

Employee

Twitter

@jnjnews

Next Earnings Date

2024-10-15

Latest SEC Filings

JNJ's Discussions on Twitter

Johnson Johnson Stock (JNJ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral
May-30-24	Resumed	Goldman	Neutral
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-01-23	Upgrade	UBS	Neutral → Buy
Oct-05-23	Initiated	RBC Capital Mkts	Outperform
Sep-06-23	Initiated	HSBC Securities	Hold
May-30-23	Resumed	Citigroup	Buy
Mar-29-23	Initiated	UBS	Neutral
Mar-01-23	Initiated	Guggenheim	Neutral
Nov-18-22	Initiated	Credit Suisse	Neutral
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-14-22	Reiterated	BofA Securities	Neutral
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-17-21	Initiated	Goldman	Neutral
Dec-15-21	Reiterated	Citigroup	Buy
Sep-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-28-21	Resumed	Morgan Stanley	Overweight
Apr-28-20	Downgrade	UBS	Buy → Neutral
Apr-22-20	Upgrade	BofA/Merrill	Neutral → Buy
Mar-05-20	Initiated	Citigroup	Buy
Dec-19-19	Upgrade	Barclays	Equal Weight → Overweight
Dec-17-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-20-19	Initiated	Cantor Fitzgerald	Overweight
Oct-16-19	Upgrade	Atlantic Equities	Underweight → Neutral
Oct-11-19	Upgrade	Bernstein	Mkt Perform → Outperform
Jul-12-19	Resumed	Credit Suisse	Outperform
May-28-19	Initiated	Goldman	Buy
Jan-23-19	Reiterated	Barclays	Equal Weight
Jul-12-18	Upgrade	Goldman	Sell → Neutral
Jun-27-18	Initiated	Bernstein	Mkt Perform
Apr-23-18	Reiterated	Citigroup	Neutral
Apr-18-18	Reiterated	Stifel	Hold
Jan-24-18	Reiterated	Stifel	Hold
Jan-12-18	Reiterated	Wells Fargo	Outperform
Jan-02-18	Downgrade	JP Morgan	Overweight → Neutral
Oct-18-17	Reiterated	RBC Capital Mkts	Outperform
Oct-18-17	Reiterated	Stifel	Hold

View All

Johnson Johnson Stock (JNJ) Latest News

04:37 AM

Johnson & Johnson Submits Application to FDA for Multiple Myeloma Treatment - MarketWatch

04:37 AM

12:25 PM

J&J clinches EC approval for first single-pill PAH combo - Pharmaceutical Technology

12:25 PM

12:23 PM

80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024 - Yahoo Finance

12:23 PM

11:59 AM

CARVYKTI® ▼ (ciltacabtagene autoleucel ; cilta-cel) est la première thérapie cellulaire à augmenter de manière significative la survie globale par rapport aux thérapies standard chez les patients atteints d’UN myélome multiple dès le traitement de deuxième intention - GlobeNewswire Inc.

11:59 AM

11:48 AM

CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) è la prima terapia cellulare a prolungare significativamente la sopravvivenza globale rispetto alle terapie standard per i pazienti con mieloma multiplo già in seconda linea - GlobeNewswire Inc.

11:48 AM

11:40 AM

Governor Kelly Directs Flags be Flown at Half-Staff in Johnson County in Honor of Former Johnson County Commission Chair Annabeth Surbaugh - Kansas Governor

11:40 AM

09:42 AM

Spanberger Leads 189-Member Bipartisan Effort Urging Administration to Protect Healthcare Providers from Johnson & Johnson’s Attempt to Hike Prescription Drug Prices - Abigail Spanberger

09:42 AM

08:57 AM

J&J Posts Positive Phase III Results for Carvykti and Darzalex Faspro in Multiple Myeloma Trials - BioSpace

08:57 AM

08:46 AM

Johnson & Johnson's (JNJ) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat

08:46 AM

08:17 AM

Johnson & Johnson rolls out new TECNIS Odyssey - TipRanks

08:17 AM

08:11 AM